Resverlogix Announces Voting Results

TSX Exchange Symbol:  RVX

CALGARY, Sept. 30, 2015 /CNW/ - Resverlogix Corp. (the "Corporation") (TSX:RVX) today announced that, at its annual and special meeting of shareholders held on September 30, 2015, each of the five nominees proposed as a director and listed in its management information circular dated August 17, 2015 were elected as directors.  Proxy voting results for each nominee are set out below:


Votes For

Votes Withheld

% For

% Withheld






Donald J. McCaffrey

32,978,486

133,690

99.60%

0.40%

Peter Johann

32,990,226

121,950

99.63%

0.37%

Kelly McNeill

32,921,276

190,900

99.42%

0.58%

Kenneth Zuerblis

33,029,776

82,400

99.75%

0.25%

Eldon Smith

32,921,176

191,000

99.42%

0.58%

About Resverlogix
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET bromodomain inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with diseases such as high-risk cardiovascular disease (CVD), diabetes mellitus (DM), Alzheimer's disease, peripheral artery disease, and chronic kidney disease while maintaining an excellent safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials. Resverlogix's Phase 3 clinical trial BETonMACE in high-risk CVD patients with DM and low HDL is planned to commence in the fall of 2015. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com. We can be followed on our blog at http://www.resverlogix.com/blog and via Twitter @Resverlogix_RVX https://twitter.com/resverlogix_rvx.

Company Contacts:

Donald J. McCaffrey
President and CEO
Resverlogix Corp.
Phone: 403-254-9252
Email: don@resverlogix.com

Sarah Zapotichny
Director, Investor Relations & Corporate Communications
Resverlogix Corp.
Phone: 403-254-9252
Email: sarah@resverlogix.com

SOURCE Resverlogix Corp.

RELATED LINKS
http://www.resverlogix.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890